Cell therapies in the clinic for heart failure draw from divergent sources of nonembryonic stem cells but collectively have shown minimal improvements in cardiac function. A University of Washington team thinks human embryonic stem cell-derived cardiomyocytes may do a better job and has used the cells to remuscularize infarcted monkey hearts.